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To provide new insights into ligand-A1 adenosine re-
ceptor (A1AR) interactions, site-directed mutagenesis
was used to test the role of several residues in the first
four transmembrane domains of the human A1AR. First,
we replaced eight unique A1AR residues with amino
acids present at corresponding transmembrane (TM) po-
sitions of A2AARs. We also tested the role of carboxamide
amino acids in TMs 1–4, and the roles of Val-87, Leu-88,
and Thr-91 in TM3. Following conversion of Gly-14 in
TM1 to Thr-14, the affinity for adenosine agonists in-
creased 100-fold, and after Pro-25 in TM1 was converted
to Leu-25, the affinity for agonists fell. After conversion
of TM3 sites Thr-91 to Ala-91, and Gln-92 to Ala-92, the
affinity for N6-substituted agonists was reduced, and
binding of ligands without N6 substituents was elimi-
nated. When Leu-88 was converted to Ala-88, the binding
of ligands with N6 substituents was reduced to a greater
extent than ligands without N6 substituents. Following
conversion of Pro-86 to Phe-86, the affinity for N6-sub-
stituted agonists was lost, and the affinity for ligands
without N6 substitution was reduced. These observa-
tions strongly suggest that Thr-91 and Gln-92 in TM3
interact with the adenosine adenine moiety, and Leu-88
and Pro-86 play roles in conferring specificity for A1AR
selective compounds. Using computer modeling based
on the structure of rhodopsin, a revised model of aden-
osine-A1AR interactions is proposed with the N
6-ade-
nine position oriented toward the top of TM3 and the
ribose group interacting with the bottom half of TMs 3
and 7.
Adenosine exerts potent biological effects in many tissues via
specific receptors that include A1 adenosine receptors (A1ARs)
1
(1–3). Because activation of A1ARs has considerable therapeu-
tic importance in treating clinical conditions (1–3), there is
considerable interest in deciphering how adenosine interacts
with A1ARs.
A1ARs are G protein-coupled receptors that have seven
transmembrane (TM) spanning domains (Fig. 1) (1–3). Initial
structure-function studies of A1ARs focused on amino acids
within TMs 5–7 (4). His-256 in TM6 was identified as a site
that interacts with antagonists (4). Within TM7, the amino acid
at position 270 was found to account for species-related differ-
ences in affinity for A1-selective drugs (5). The amino acid at
position 277 was shown to interact with the 59 position of the
adenosine ribose moiety (6). It was also suggested that His-278
in TM7 is important for ligand binding (4).
More recently, studies of chimeric A1/A2AARs have shown
that TMs 1–4 of A1ARs contain the sites that confer the ligand
binding characteristics of an A1AR (7). Because modification of
the N6 adenine position confers A1AR selectivity of adenosin-
ergic compounds (8), this observation strongly suggests that
the N6-adenine position interacts with sites within TMs 1–4
(7). Within the first four TM domains of the A1AR, mutation of
Glu-16 in TM1 results in broad decreases in agonist affinity,
and mutation of Ser-94 in TM3 results in a complete loss in
ligand binding (7). Yet, despite these observations, a clear
understanding of how adenosine interacts with A1ARs is not at
hand.
To provide additional insights into how ligands interact with
A1ARs, we have tested the potential roles of several amino
acids in TMs 1–4 in ligand binding. First, we have replaced
amino acids within TMs 1–4 of A1ARs with amino acids pres-
ent at corresponding positions in A2AARs. We have also exam-
ined the potential roles of carboxamide and several other amino
acids in TM3. Using these approaches, we now identify puta-
tive binding sites in TM3 that interact with the adenosine
adenine group and a revised model of ligand-A1AR interactions
is proposed.
EXPERIMENTAL PROCEDURES
cDNAs—The cDNA encoding the full-length human A1AR was pro-
vided by Dr. S. M. Reppert (Boston, MA). This cDNA has been exten-
sively characterized (9).
Generation of Mutant Receptors—Mutant receptors were made by the
polymerase chain reaction (PCR) overlap-extension method (10).
Primer pairs were designed to introduce mutations as described (11).
Oligonucleotides were synthesized using an Applied Biosystems Oligo-
nucleotide Synthesizer (Foster City, CA). To generate the front part of
mutant receptors, oligonucleotide primer pairs (primers A and B) were
designed to generate a 59 fragment of the A1AR. Another set of oligo-
nucleotide primer pairs (primers C and D) was designed to generate a
39 fragment of the A1AR receptor. B and C primers contained sequences
that encoded for the desired mutations.
Receptor fragments were generated using 1 mg of DNA as the sub-
strate for PCR reactions, and PCR reactions were performed using the
Gene Amp Kit reagents (Perkin Elmer). PCR was generally performed
using 30 cycles at 94 °C for 1 min, 55 °C for 1 min, and 72 °C for 2 min.
PCR products were then separated on a 1% agarose gel and eluted.
Receptor fragments (A-B and C-D) were then combined in a third PCR
reaction to generate a full-length A1AR using flanking primers (A and D).
Flanking PCR primers contained HindIII (A primers) or Xbal (D
primers) restriction endonuclease sites at the ends. After fusion reac-
tions, PCR products were digested with HindIII and Xbal and were
subcloned into the mammalian expression vector pcDNA3 (Invitrogen;
San Diego, CA). Mutant receptors were then sequenced.
Acute Transfections—Receptor cDNA expression was characterized
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using COS-7 cells as described (12). COS cells were grown as monolay-
ers in Dulbecco’s minimal essential medium (DMEM; Life Technologies,
Inc.) supplemented with 10% fetal calf serum, penicillin (100 units/ml),
and streptomycin (100 g/ml), in 5% CO2 at 37 °C. Cells were acutely
transfected using the DEAE-dextran method. 10-cm plates were indi-
vidually transfected with 5–10 mg of DNA, or were sham transfected. At
48–72 h after transfection, cells were tested by radioreceptor assay.
Under those conditions, we found that there was very little evidence of
receptor-G protein coupling (7), similar to that as reported by others (5).
Radioreceptor Assays—Radioligand binding studies were performed
using intact cells as described (7, 11). The radioligands used were
[3H]CCPA (NEN Life Science Products, Boston, MA; specific activity, 33
Ci/mmol) and [3H]DPCPX (NEN Life Science Products; specific activity,
100 Ci/mmol). All determinations were done in quadruplicate. When
constructs with different levels of expression were compared, we ad-
justed tissue per tube so that amounts of specific binding per tube were
similar among the different constructs.
Molecular Modeling—A model for the human A2AAR deposited in the
Protein Data Bank (entry 1mmh) by Van Rhee and co-workers (13) was
used for construction of our model of the human A1AR. First, the helical
parts of the two sequences retrieved from the GPCR DataBase Project2
were aligned as described by IJzerman et al. (14) for the canine A1 and
A2A receptors. Subsequently, all amino acid differences between the
canine and human A1ARs were identified and converted to human
A1AR motifs. NECA, the ligand present in the A2A receptor model, was
changed to CPA, which is the reference agonist for A1ARs. Steric
clashes between amino acid side chains and CPA were removed by
rotation of side chains only. Guided by the results from the mutagenesis
studies presented in this report, we included Leu-88, Thr-91, and
Gln-92 in a putative N6-binding region. As a consequence, Ser-94,
Thr-277, and His-278 were found to be close to the ribose moiety of CPA.
After these manipulations, a short minimization procedure with default
parameters was followed in which all side chains within 4 Å of CPA
were relaxed. All calculations were performed with the software pack-
age QUANTA 96 (MSI, Waltham, MA, USA) running on a Silicon
Graphics Indigo O2 workstation.
Statistical Analysis—Saturation and competition binding data were
analyzed by computer using an iterative nonlinear regression program
(15). Comparisons among multiple groups were performed by one-way
analysis of variance, with post-test comparison among groups per-
formed by the Bonferroni method. Comparisons between paired groups
were performed by the paired t test. The InStat, Vers. 3, statistics
program (GraphPad; San Diego, CA) was used for statistical
computations.
Drugs—All adenosinergic compounds tested were obtained from Re-
search Biochemicals Inc. (Natick, MA).
RESULTS
Experiment 1, A1ARs/A2AAR Amino Acid Transposition
Studies in TMs 1, 2, and 4—To identify potential sites within
TMs 1–4 that may play a role in conferring binding properties
of A1ARs, differences in the amino acid sequences of A1 and
A2AARs were identified. First, the amino acid sequences of all
cloned A1ARs and A2AARs within TMs 1–4 of different species
present in the GenBankTM data base were compared to identify
common amino acids among the different species. Universal
differences among all A1ARs and A2AARs were then identified.
Using site-directed mutagenesis, human A1AR residues were
replaced by the corresponding amino acids of A2AARs. Satura-
tion studies were then performed using [3H]CCPA or [3H]D-
PCPX (Table I). Competition studies were next performed us-
ing a fixed dose of [3H]DPCPX and graded doses of DPCPX or
CPA and several other compounds (Table II). These studies
revealed similar ligand binding properties for the WT-A1AR
and Cys-31, Phe-65, Phe-82, Lys-125, and Leu-144 mutant
A1AR constructs (Tables 1 and 2). In contrast, when the WT-
A1AR and the Gly-14 3 Thr-14 constructs were compared,
markedly increased affinity for agonists was seen for the mu-
tant receptor, and when the Pro-25 3 Leu-25 construct was
examined, the affinity for agonists fell (Tables 1 and 2).
Experiment 2, Mutations of Carboxamide Amino Acids—Pre-
vious attempts aimed at modifying several hydroxyl or polar
amino acids within TMs 1–4 that are unique to A1ARs domains
failed to identify a site that interacts with the adenine N6
position (11). Therefore, we examined the role of carboxamide
sites within TMs 1–4 (Asn-70, Gln-92). These amino acids
contain oxygen and nitrogen atoms that may form hydrogen
bonds with similar atoms in adenosine. Ala-70 and Ala-92
constructs were thus generated and tested. Competition stud-
ies were then performed using a fixed dose of [3H]DPCPX and
graded doses of CPA or DPCPX. When the Ala-70 construct was
tested, no differences in affinity for ligands were seen in com-
parison with studies of the WT-A1AR. In contrast, the Ala-92
construct had markedly reduced affinity for CPA.
Next, to assess potential regions of the adenosine molecule
that could interact with Gln-92, competition studies were per-
formed using compounds with (CPA, R-PIA) or without (NECA,
2 chloroadenosine) N6 substitutions. In comparison with that2 On WWW site: http://swift.embl-heidelberg.de/7tm/.
FIG. 1. Schematic representation of
the human A1AR. Sites that were mu-
tated in this report are represented by
black circles.
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observed for the WT-A1AR, the affinity of each compound for
the Ala-92 construct was markedly reduced. However, reduc-
tions in affinity for NECA and CADO were greater than reduc-
tions in affinity for CPA or R-PIA. When competition studies
were performed using the compound N-0840, which is struc-
turally similar to CPA but lacks a ribose group, the Ala-92
construct had markedly reduced affinity for the ligand as com-
pared with the WT-A1AR.
Experiment 3, Additional Site-directed Mutagenesis Studies
in TM3—Because the above studies suggest that Gln-92 inter-
acts with the adenine group, we next examined the role of other
amino acids within TM3. First, we performed additional A1/
A2AAR transposition studies at sites in TM3 (Pro-863 Phe-86,
Leu-963 Phe-96). Competition studies showed that conversion
of Leu-96 to Phe-96 did not alter ligand binding properties.
However, after conversion of Pro-86 to Phe-86, the binding of
N6-substituted ligands (CPA, R-PIA) to the mutant construct
was reduced more than 10-fold (Table II).
Next, we tested the roles of Val-87, Leu-88, and Thr-91 in
TM3 by converting these sites to alanine residues. Following
conversion of Val-87 to Ala-87, no changes in ligand binding
characteristics were seen (Table III). However, after Leu-88 or
Thr-91 was converted to Ala, marked reductions in the affinity
for agonists were observed (Table III). Competition studies
were next performed using the compound N-0840. Suggesting
that Thr-91 interacts with the adenine group, this construct
had nearly 100-fold reduced affinity for N-0840.
Experiment 4, Computer Modeling—Considering the above
results suggesting that Thr-91 and Gln-92 influence adenine
binding, molecular modeling of CPA-A1AR interactions was
performed based on the structure of rhodopsin (16). The results
of computer modeling experiments are illustrated in Fig. 2. In
Fig. 2A, the upper part of the purine ring and the N6-substit-
uent of CPA are shown interacting with residues on TM3 that
were mutated in the present study (Thr-91 and Gln-92). Fig. 2B
represents the same interaction shown from a different angle.
Because of the helical nature of TM3, Pro-86 cannot be brought
close to CPA if Thr-91 and Gln-92 interact with CPA in a direct
way (see also Fig. 2). Leu-88, however, is close to the cyclopen-
tyl group of CPA, in line with its more prominent influence on
the binding of N6-substituted agonists (CPA and R-PIA) than of
NECA and CADO, both agonists without N6-substituents. Val-
87, more distant from the cyclopentyl group than Leu-88, does
not influence binding.
Positioned in the manner shown, CPA will also interact with
TM7, which is highlighted in Fig. 2C. The ribose moiety is close
to Thr- 277 and His-278 and also to Ser-94 (TM3), which are all
amino acids shown to influence ligand binding (5, 6).
DISCUSSION
Studies of A1AR-ligand interactions have largely focused on
the importance of sites in TMs 6–7 and have been used to
generate models of adenosine-A1AR interactions (4–6). In
these models, it is suggested that the ribose group interacts
with TM7 and the adenine group interacts with TMs 6 and 7
(4–6). Based on the results of the site-directed mutagenesis
studies presented in this report, a revised model of ligand-
A1AR interactions is proposed in which the adenine group
interacts with TM3, and the ribose group interacts with TMs 3
and 7.
Modifications present on the N6 adenine position determine
whether a ligand will be selective for A1ARs (8). Foremost in
identifying potential residues that can interact with the N6
position is consideration of chimeric receptor studies showing
that TMs 1–4 confer the ligand binding properties of A1ARs (7).
Thus, it is very likely that the N6 binding site will be located
within TMs 1–4. Of the sites that we have tested, only muta-
tions of Leu-88, Thr-91, or Gln-92 resulted in the differential
TABLE I
Binding affinities for [3H]CCPA and [3H]DPCPX in A1/A2A transposition studies
All values are means of three to six separate studies per construct. S.E. values are given when there are three or more studies per construct. *,
p , 0.05 by analysis of variance with Bonferroni post-test comparison versus wild type A1AR.
Receptor construct
[3H]CCPA [3H]DPCPX
Kd Bmax Change (from WT) Kd Bmax Change (from WT)
nM fmol/mg nM fmol/mg
WT A1AR 0.6 6 0.15 550 6 62 0.7 6 0.2 565 6 75
A1AR 3 A2AAR
Gly14 3 Thr14 0.007 6 0.02* 550 6 62 0.011 0.8 6 0.3 650 6 34 1.1
Pro25 3 Leu25 1.8 6 0.2* 230 6 80 3.0 0.7 6 0.2 346 6 76 1.0
Ile31 3 Cys31 0.7 6 0.1 458 6 34 1.2 0.8 6 0.2 546 6 25 1.1
Leu65 3 Phe65 0.6 6 0.1 568 6 54 1.0 0.7 6 0.4 498 6 66 1.0
Met82 3 Phe82 0.7 6 0.2 412 6 23 1.2 0.8 6 0.2 426 6 21 1.1
Ala125 3 Lys125 0.7 6 0.1 569 6 81 1.2 0.7 6 0.2 512 6 85 1.0
Phe144 3 Leu144 0.6 6 0.2 396 6 43 1.0 0.8 6 0.2 456 6 84 1.1
TABLE II
KI values from competition of [
3H]DPCPX binding in A1/A2A transposition studies
Values are means of three or more separate studies per drug in which samples were tested in quadruplicate in each study in side-by-side studies
with the wild-type human A1AR. *, p , 0.05 by analysis of variance with Bonferroni post-test comparison versus WT-A1AR.
Drug
KI values
Gly 3 Thr14 Pro 3 Leu25 Pro 3 Phe86 WT A1AR
M
NECA 7.0 6 4.3 E-7 1.5 6 2.2 E-5* .1 E-5* 5.1 6 2.1 E-6
Change from WT 0.13 2.9 .10
CADO 6.0 6 2.7 E-9* 2.2 6 3.3 E-5 6.2 6 2.3 E-5* 5.6 6 3.2 E-6
Change from WT .001 3.9 11.1
R-PIA 2.7 6 0.9 E-9* 1.3 6 0.4 E-6 4.4 6 1.2 E-5* 3.7 6 0.8 E-7
Change from WT 0.07 3.5 118
CPA 1.2 6 1.2 E-9* 7.9 6 2.6 E-6* 1.27 6 1.3 E-5* 1.3 6 1.2 E-7
Change from WT .009 60 92
DPCPX 4.3 6 1.2 E-9 3.3 6 1.3 E-9 1.6 6 0.3 E-9 2.2 6 0.2 E-9
Change from WT 1.9 1.5 0.7
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reduction in the affinity of N6-substituted and non-substituted
ligands, suggesting that Leu-88, Thr-91, and Gln-92 interact
with the N6 substituents. Other investigators have also ob-
served differential reduction in the affinity of N6-substituted
(R-PIA) and non-substituted ligands (NECA) when the binding
characteristics were compared for Thr-277 mutations (6). How-
ever, this reflects differences in binding of ribose substituents,
not N6 substituents (6).
When we modified sites in TM1, we found that conversion of
Gly-14 to Thr-14 resulted in increased affinity for agonists. In
contrast, modification of Glu-16 in A1ARs and Glu-11 in
A2AARs has been shown to result in decreased agonist affinity
(11, 17). To date, direct interactions between small molecule
ligands and sites in TM1 have yet to be demonstrated (18, 19).
However, because molecular modeling studies suggest that
TM1 is juxtaposed with TM7 (16, 18, 19), it is possible that
TM1 mutations indirectly influence ribose-TM7 interactions.
Although less likely, we also recognize the possibility that
ribose-hydroxy groups may interact with polar TM1 sites.
Adenosine has several sites that can potentially interact
with receptor amino acids (8). The adenine group contains five
nitrogen atoms (N1, N3, N6, N7, and N9) that can interact with
receptor sites, whereas the ribose moiety contains three hy-
droxyl groups (29, 39, 59) (8). Within the adenine group, removal
of either of the N6, N7, and N9 nitrogen atoms results in more
than a 1000-fold loss in affinity for A1ARs (8). Removal of the
N1 and N3 nitrogen molecules results in 10- and 100-fold re-
ductions in affinity for A1ARs, respectively (8). The three ri-
bose-hydroxyl groups also are very important for binding, as
removal of these groups results in significant reduction in the
affinity for A1ARs (8).
Previous models of adenosine-A1AR interactions have been
guided by site-directed mutagenesis studies of sites in TMs 5–7
(14). Considering the possible importance of His-250 in TM6
and His-278 in TM7, IJzerman and co-workers (14) proposed
that the 29 and 39-hydroxyl groups of CPA interact with His-
278, and the N6 position interacts with His-250 in TM6. How-
ever, the primary amino acid sequence is very similar between
A1 and A2AARs in this putative N
6 binding region (14), making
it difficult for this model to account for the considerably differ-
ent binding properties of A1AR and A2AARs.
In the past, models for the adenosine A1, A2A, and A3ARs
receptor have been based on the structural template of bacte-
riorhodopsin (14, 20, 21). Since those studies, the structure of
mammalian rhodopsin has been studied in greater detail (16),
revealing similarity to the structure of bacteriorhodopsin. The
relative positions of the TMs 3 and 7 in rhodopsin, however, are
closer to each other than in bacteriorhodopsin (16). Considering
the importance of sites in TM3 and TM7 on ligand-A1AR inter-
actions shown in these and other studies (4–6), we therefore
decided to generate a rhodopsin-based model for the human
A1AR. As shown in Fig. 2C, TMs 3 and 7 are in close proximity
in this A1AR model, particularly where the ribose moiety of
CPA is suggested to bind to Ser-94, Thr-277, and His- 278,
which are residues that are essential for agonist binding (6, 11).
Our model also suggests that the adenine group interacts
with TM3. There is considerable support for this notion. First,
mutation of residues in the human adenosine A2AAR sites that
are equivalent to Thr-91 and Gln-92 have been shown to affect
ligand binding (13). Second, photoaffinity labeling studies us-
TABLE III
KI values from competition of [
3H]DPCPX binding in TM3 site-directed mutagenesis studies
Values are means of three or more separate studies per drug in which samples were tested in quadruplicate in each study in side-by-side studies
with the wild-type human A1AR. *, p , 0.05 by analysis of variance with Bonferroni post-test comparison versus wild type A1AR.
Drug
KI values
Val 3 Ala87 Leu 3 Ala88 Thr 3 Ala91 Gln 3 Ala92 WT A1AR
M
NECA 4.2 6 4.3 E-6 1.5 6 0.3 E-4* 7.7 E-4* .1 E-4* 5.1 6 2.1 E-6
Change from WT 0.82 29.4 150 .200
CADO 1.3 6 2.9 E-6 1.1 6 0.4 E-6 .1 E-4* .1 E-4* 1.0 6 2.2 E-6
Change from WT 1.3 41 .100 .180
R-PIA 2.6 6 1.1 E-7 1.8 6 0.4 E-4* 7.2 6 1.2 E-5* 2.6 6 0.7 E-5* 3.6 6 2.4 E-7
Change from WT 0.72 500 200 72
CPA 5.5 6 1.0 E-7 4.2 6 2.6 E-5* 9.7 6 3.3 E-6* 1.3 6 1.2 E-5* 5.6 6 3.2 E-7
Change from WT 1.0 75 17 23
N 0840 2.3 6 1.2 E-6 .1 E-4* .1 E-4* .1 E-4* 7.5 6 1.2 E-7
Change from WT 3.0 .100 .100 .100
FIG. 2. Computer modeling of CPA-A1AR interactions. A and B, CPA interactions with TM3 shown from two different perspectives. C,
CPA-ribose interactions with TM3 (left helix) and TM7 (right helix) residues.
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ing an antagonist compound show that adenosinergic com-
pounds interact with TM3 (22). Third, mutation of sites in TM3
alter the binding of the antagonist N-0840, which can be re-
garded as CPA without the ribose moiety (8). Structure-activity
relationships for N6-substituted adenines like N-0848 are quite
similar to those of N6-substituted adenosines (23), indicating
that the N6-substituents of both adenosine agonists and ade-
nine antagonists coincide and occupy the same binding site.
The compound N-0861, the norbornanyl variant of N-0840, also
is very selective for A1, supporting the notion that the N
6-
substituents of N-0840 and CPA coincide (24).
Based on our model, the two aliphatic, lipophilic residues
Val-87 (the equivalent of the aspartate residue important for
binding in many biogenic amine receptors) and Leu-88 could
have a favorable interaction with the N6-cyclopentyl substitu-
ent in CPA. However, mutation studies showed that only
Leu-88 influences the binding of N6-substituted agonists, with
the affinity for R-RIA reduced by the greatest extent. Because
R-PIA has the longest and most hydrophobic N6-side chains of
the ligands tested (8), these observations support the notion
that Leu-88 interacts with hydrophobic N6-substituents. Addi-
tional support for this possibility comes from observations that
mutations at Thr-91 and Gln-92 affected CPA binding less than
NECA or CADO binding. Interaction of N6-substituents with
Leu-88 may thus facilitate agonist in the absence of sites that
interact with the nitrogen ring, possibly at the N6 nitrogen.
The Pro-863 Phe-86 mutation also induced broad decreases
in the affinities of all compounds studied. However, our model
suggests that this is an indirect effect, as Pro-86 is quite distant
from CPA. Thus, it is possible that Pro-86 alters the conforma-
tion of TM1 in A1ARs to favor the binding of N
6-substituents to
A1ARs.
We recognize that our model does not yet accommodate the
role of other sites that may influence the conformational state
of A1ARs and indirectly influence adenosine-A1AR interac-
tions. As mentioned above, modification of sites in TM1 of
A1ARs (Thr-14, Glu-16) and A2AARs (Glu-13) induces broad
changes in the affinity for agonists, whereas Asp-55 in TM2 of
A1ARs mediates allosteric effects of sodium ions on ligand
binding (11). Sites in the second extracellular loop also may
influence adenosine-AR interactions (25). Considering the
large number of potential interaction sites in the adenosine
molecule (8), it is therefore likely that adenosine ligand-recep-
tor interactions will be quite complex. For the present, our
revised model of CPA-A1AR interactions, now provides a con-
ceptual framework for explaining the role of TM3 in ligand
binding and A1AR ligand selectivity.
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